PepGen Inc. (PEPG)
- Previous Close
1.4300 - Open
1.4400 - Bid 1.5000 x 100
- Ask 1.5600 x 100
- Day's Range
1.4200 - 1.5500 - 52 Week Range
0.8800 - 19.2980 - Volume
156,532 - Avg. Volume
2,719,768 - Market Cap (intraday)
50.39M - Beta (5Y Monthly) 1.39
- PE Ratio (TTM)
-- - EPS (TTM)
-3.1400 - Earnings Date Aug 6, 2025 - Aug 13, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
11.60
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and PGN-EDO53, which is in preclinical trial to treat duchenne muscular dystrophy. The company was founded in 2018 and is based in Boston, Massachusetts.
pepgen.comRecent News: PEPG
View MorePerformance Overview: PEPG
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PEPG
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PEPG
View MoreValuation Measures
Market Cap
50.39M
Enterprise Value
-29.12M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.55
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-40.84%
Return on Equity (ttm)
-75.45%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-102.16M
Diluted EPS (ttm)
-3.1400
Balance Sheet and Cash Flow
Total Cash (mrq)
97.78M
Total Debt/Equity (mrq)
19.91%
Levered Free Cash Flow (ttm)
-46.26M